In-stent restenosis is the major problem of percutaneous coronary interventions. Drug-eluting stent became a landmark in the treatment of coronary disease. Curcumin could be used for drug-eluting stent due to its antithrombogenity and antiproliferative properties. In this paper, 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assays were performed to decide the optimal concentration of curcumin for inhibiting the proliferation of vascular smooth muscle cells (VSMC). The result disclosed that more than 80% of VSMC were inhibited when the concentration of curcumin ranged from 2.5 microg/ml to 10 microg/ml (P < 0.05, compared to ethanol). Three weight percent curcumin-loaded films (3wt%, 5wt%, 8wt%) were prepared using a biodegradable polymer (poly (lactic acid-co-glycol acid), PLGA) as the carrier of curcumin. The release of lactate dehydrogenase (LDH) was used to evaluate the immediate toxicity of the curcumin-loaded PLGA films, and the three concentration curcumin-loaded films were revealed to be of no acute toxicity to the smooth muscle cells. The results of Alamar Blue test indicated that the curcumin-loaded films had better antiproliferation effect than did the 316 stainless steel (SS). Therefore, these films may be used for stent coating to inhibit the in-stent restenosis induced by VSMC proliferation.
Angioplasty, Balloon, Coronary ; Animals ; Carotid Arteries ; cytology ; Cell Proliferation ; drug effects ; Cells, Cultured ; Coated Materials, Biocompatible ; pharmacology ; Coronary Restenosis ; prevention & control ; Curcumin ; pharmacology ; Drug-Eluting Stents ; Lactic Acid ; pharmacology ; Muscle, Smooth, Vascular ; cytology ; Polyglycolic Acid ; pharmacology ; Rats

In-stent restenosis is the major problem in clinical application of coronary stent. Drug-eluting stent became a landmark in the treatment of coronary disease. However, thrombosis is still a problem of drug-eluting stent. There has been clinical report indicating that thrombosis sometimes is induced by drug-eluting stent implantation in late stage. Curcumin could be used for drug-eluting stent due to its antithrombogenity and antiproliferative properties. In this paper, three weight percent curcumin-loaded films (3wt%, 5wt%, 8wt%) were prepared using a biodegradable polymer (poly (lactic acid-co-glycol acid), PLGA) as the carrier of curcumin. The component of curcumin-loaded film was analyzed by Fourier transform infrared spectroscopy (FTIR), and the major peaks of curcumin and PLGA were both observed in the composite film. The result of in vitro platelet adhesion test shows that the number of adhered platelet reduces, and few aggregated and activated platelets are observed. For all composite films, activated partial thromboplastin time (APTT) increases. The results indicate that the curcumin-loaded films have better anticoagulative effect when compared with PLGA. In addition, all anticoagulation tests indicate "the higher the drug content in the film, the better the anticoagulative effect".
Coated Materials, Biocompatible ; pharmacology ; Coronary Restenosis ; prevention & control ; Curcumin ; pharmacology ; Drug-Eluting Stents ; Humans ; Lactic Acid ; pharmacology ; Platelet Adhesiveness ; drug effects ; Platelet Aggregation Inhibitors ; pharmacology ; Polyglycolic Acid ; pharmacology ; Polymers